VERU INC (VERU) Stock Price, Forecast & Analysis
USA - NASDAQ:VERU - US92536C2026 - Common Stock
VERU Key Statistics, Chart & Performance
The current stock price of VERU is 2.51 USD. In the past month the price decreased by -39.81%. In the past year, price decreased by -56.99%.
VERU Latest News, Press Relases and Analysis
VERU Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.52 | 968.11B | ||
| JNJ | JOHNSON & JOHNSON | 18.81 | 470.23B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.12B | ||
| PFE | PFIZER INC | 8.06 | 146.63B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.41 | 98.98B | ||
| ZTS | ZOETIS INC | 19.11 | 53.70B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 23.17B | ||
| VTRS | VIATRIS INC | 4.68 | 12.72B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.91 | 10.92B | ||
| CORT | CORCEPT THERAPEUTICS INC | 86.08 | 7.98B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.86B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 3.90B |
Related stock screener links
About VERU
Company Profile
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company is headquartered in Miami, Florida and currently employs 210 full-time employees. Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Company Info
VERU INC
2916 N. Miami Avenue, Suite 1000
Miami FLORIDA 33127 US
CEO: Mitchell S. Steiner
Employees: 210
Phone: 13125959123
VERU INC / VERU FAQ
Can you describe the business of VERU INC?
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company is headquartered in Miami, Florida and currently employs 210 full-time employees. Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
What is the current price of VERU stock?
The current stock price of VERU is 2.51 USD. The price decreased by -8.06% in the last trading session.
Does VERU stock pay dividends?
VERU does not pay a dividend.
What is the ChartMill technical and fundamental rating of VERU stock?
VERU has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for VERU stock?
10 analysts have analysed VERU and the average price target is 21.68 USD. This implies a price increase of 763.55% is expected in the next year compared to the current price of 2.51.
How many employees does VERU INC have?
VERU INC (VERU) currently has 210 employees.
VERU Technical Analysis
VERU Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VERU. While VERU seems to be doing ok healthwise, there are quite some concerns on its profitability.
VERU Financial Highlights
Over the last trailing twelve months VERU reported a non-GAAP Earnings per Share(EPS) of -2.2. The EPS decreased by -126.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -96.59% | ||
| ROE | -144.48% | ||
| Debt/Equity | 0 |
VERU Forecast & Estimates
10 analysts have analysed VERU and the average price target is 21.68 USD. This implies a price increase of 763.55% is expected in the next year compared to the current price of 2.51.
For the next year, analysts expect an EPS growth of -4.58% and a revenue growth -100% for VERU